Navigation Links
Alaven Pharmaceutical Introduces Kit for UC Patients
Date:6/9/2008

MARIETTA, Ga., June 9 /PRNewswire/ -- When patients with ulcerative colitis (UC) flare, their normal life can be completely disrupted. Bloody diarrhea, frantic urgency and abdominal pain make the bathroom the center of attention.

Alaven Pharmaceutical LLC, a specialty pharmaceutical company focused on developing and commercializing products to treat gastrointestinal conditions, today announced the introduction of a convenience Kit at the American Society of Colon and Rectal Surgeons' annual meeting in Boston. The Kit contains ROWASA(R) (mesalamine) Rectal Suspension Enema 4g/60mL, a treatment for flare symptoms associated with active mild to moderate left-sided UC, proctosigmoiditis, or ulcerative proctitis, and a personal cleansing wipe for added convenience for those inevitable restroom stops.*

"There is a continued need in the marketplace for convenient UC therapy for all patients living with the disease and facing the inevitability of flares," said Connie Swanson, VP, Sales and Marketing at Alaven. "Our hope is that by offering ROWASA in a convenience kit, patients will have access to a soothing topical treatment for more immediate flare relief and that they will be more comfortable with their medication-taking routine."

ROWASA is a prescription medication administered at bedtime for the relief of UC flare symptoms. Applied directly to the site of inflammation, ROWASA reduces rectal bleeding in as little as 3 days(1) and provides fast relief of diarrhea, abdominal pain, and other flare symptoms(2). The full course of treatment with ROWASA (3-6 weeks) is recommended for more complete flare relief(2).

Due to the unpredictable course of UC that is marked by periods of inactivity and then incidences of intermittent flares, patients are at an increased risk for poor adherence to medications. An estimated 34% of patients with left-sided UC have been shown to be non-compliant to prescribed medications(3). Research also shows that innovative ways, including providing convenient medications, may help to motivate patients to adhere(3).

The ROWASA convenience kit helps to improve the delivery and accessibility to reliable UC flare therapy while offering value-added convenience from a personal cleansing wipe that leaves UC patients clean and fresh.*

For additional information, visit http://www.ROWASA.com .

Important Safety Information

Contraindications: ROWASA is contraindicated for patients known to have hypersensitivity to the drug or any component of this medication.

Warning: ROWASA contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low.

Precautions: Mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. Caution should be exercised when mesalamine is initially used in patients known to be allergic to sulfasalazine.

Adverse Reactions: ROWASA is usually well tolerated. Most adverse effects have been mild and transient. The most frequently reported adverse events include abdominal cramps, headache, gas, nausea, flu, fatigue, fever and rash.
For Full Prescribing Information - http://www.ROWASA.com .

*Wipe is optional and not a required part of treatment

1 Sutherland LR, et al. 5-aminosalicylic acid enema in the treatment of

distal ulcerative colitis, proctosigmoiditis, and proctitis.

Gastroenterology. 1987;92(6):1894-1898.

2 ROWASA Prescribing Information. Rev 05/08.

3 Kane SV, et al: The Challenge of Compliance and Persistence: Focus on

Ulcerative Colitis. J Manag Care Pharm. 2008;14(1)(suppl S-a):S2-S12.

Contact: Rose Raus

404-964-1834

rraus@dodgecommunications.com


'/>"/>
SOURCE Alaven Pharmaceutical LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce ... South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge ... of their homes, offices or at the practices’ local office. It is also one ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for American ... and wellness best practices in the past couple of decades, and food manufacturers ... Heart Month, which acts as an exceptional opportunity to revise food labels and ...
(Date:2/10/2016)... ... 10, 2016 , ... President Obama’s budget proposal yesterday enables ... medical services via telehealth, estimated to generate more than $160 million in savings ... many years. Although there is more to be done, this represents an ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... PLAD, Inc. (OTC Pink: PLAD) is pleased to announce ... company targets, are adding key personnel to their national ... United States Patent and Trademark Office for the characters ... of PLAD, Inc.  In January, PLAD established their presence ... with two new customers, Cumberland Goodwill EMS and Meadville ...
(Date:2/11/2016)... 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , ... an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the ...
Breaking Medicine Technology: